Clarient, Inc.
Formerly ChromaVision Medical Systems, Inc., MicroVision Medical Systems, Inc.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2009 | $11 M | Issued in a merger or acquisition | $10 to $50 million | equity, options | SEC | |
| Mar 2009 | $29 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Clarient, Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (Dec 2009).
SEC Form D (revenue range) · Dec 2009
The industry group it chose in its notices: Other Health Care.
SEC Form D · Dec 2009
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Clarient, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David J. Daly | Executive officer | Dec 2009 |
| Michael J. Pellini | Executive officer | Dec 2009 |
| Michael R. Rodriguez | Executive officer | Dec 2009 |
| Ron J. Collette | Executive officer | Dec 2009 |
| Ronald A. Andrews | Executive officer | Dec 2009 |
| Raymond J. Land | Executive officer | Apr 2009 |
| Andrew H. Adams | Director | Dec 2009 |
| Ann H. Lamont | Director | Dec 2009 |
| Dennis M., Jr. Smith | Director | Dec 2009 |
| Frank P., Jr. Slattery | Director | Dec 2009 |
| Gregory D. Waller | Director | Dec 2009 |
| James A. Datin | Director | Dec 2009 |
| Peter J. Boni | Director | Dec 2009 |
| Ronald A. Andrews | Director | Dec 2009 |
| Stephen T. Zarrilli | Director | Dec 2009 |
| Andrew Adams | Director | Apr 2009 |